NEW DRUG APPROVALS Blincyto for Rare Form of ALL The FDA has approved blinatumomab (Blincyto, Amgen) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL). Precursor B-cell ALL is a rapidly growing cancer in which the bone marrow makes too many B-cell lymphoblasts. The Philadelphia chromosome is an abnormality that sometimes occurs in...

I have read the contribution of Gökbuget et al. with interest. The authors compared outcomes of a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical dataset from Europe and the United States. The clinical efficacy of blinatumomab against the historical data was analyzed with different stati...

Objective To evaluate the clinical efficacy and safety of a short course blinatumomab in children with refractory or relapsed precursor B-cell acute lymphoblastic leukemia (R/R-BCP-ALL). Methods The data 33 R/R BCP-ALL aged 0–18 years who underwent (14 days) between August 2021 November 2022 were retrospectively collected analyzed. Results Among patients BCP-ALL, 26 achieved complete remission ...

Blinatumomab, the bispecific T cell engager, has been demonstrated as the most successful BsAb to date. Throughout the past decade, vector design has great importance for the expression of monoclonal antibody in Chinese hamster ovary (CHO) cells. It has been indicated that expression plasmids based on the elongation factor-1 alpha (EF-1 alpha) gene and DHFR selection marker can be highly effect...